Thermo Fisher Scientific Inc. (NYSE:TMO) Plans $0.39 Quarterly Dividend

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) declared a quarterly dividend on Wednesday, May 22nd, RTT News reports. Investors of record on Friday, June 14th will be paid a dividend of 0.39 per share by the medical research company on Monday, July 15th. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%.

Thermo Fisher Scientific has raised its dividend payment by an average of 16.7% per year over the last three years and has raised its dividend every year for the last 7 years. Thermo Fisher Scientific has a dividend payout ratio of 6.4% meaning its dividend is sufficiently covered by earnings. Analysts expect Thermo Fisher Scientific to earn $23.97 per share next year, which means the company should continue to be able to cover its $1.56 annual dividend with an expected future payout ratio of 6.5%.

Thermo Fisher Scientific Stock Performance

TMO stock traded up $0.68 during midday trading on Wednesday, reaching $590.80. 871,441 shares of the company were exchanged, compared to its average volume of 1,510,454. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The business has a 50-day moving average price of $576.49 and a two-hundred day moving average price of $545.39. Thermo Fisher Scientific has a one year low of $415.60 and a one year high of $603.82. The firm has a market capitalization of $225.52 billion, a price-to-earnings ratio of 37.85, a price-to-earnings-growth ratio of 2.46 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping analysts' consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The firm had revenue of $10.35 billion during the quarter, compared to analysts' expectations of $10.14 billion. Equities research analysts forecast that Thermo Fisher Scientific will post 21.65 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on TMO. Royal Bank of Canada boosted their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an "outperform" rating in a research note on Thursday, February 1st. HSBC boosted their price target on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a "buy" rating in a research note on Tuesday, April 30th. JPMorgan Chase & Co. boosted their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an "overweight" rating in a research note on Thursday, April 25th. Deutsche Bank Aktiengesellschaft boosted their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a "buy" rating in a research note on Thursday, April 25th. Finally, Barclays boosted their target price on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an "equal weight" rating in a research note on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and a consensus target price of $607.35.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $74,039,491.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the firm's stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares of the company's stock, valued at approximately $7,430,359.02. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company's stock, valued at $74,039,491.68. The disclosure for this sale can be found here. Insiders sold a total of 32,000 shares of company stock worth $18,486,980 in the last quarter. Insiders own 0.34% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.